The biological story begins with mitophagy, the selective autophagic disposal of damaged mitochondria. When this quality-control system falters, worn-out mitochondria linger in the cell and leak their DNA into the cytoplasm. Cytosolic mitochondrial DNA is not inert debris; it acts as a damage-associated molecular pattern that mimics a viral invasion. The cell’s innate immune surveillance machinery, chiefly the cyclic GMP–AMP synthase–stimulator of interferon genes pathway, better known as cGAS–STING, detects the misplaced DNA and ignites inflammatory and degenerative programmes. In the context of the disc, where cells already endure a harsh, nutrient-poor and acidic environment, this false alarm can push them over the edge into senescence and apoptosis.

What makes the new work distinctive is the identification of a downstream effector that translates this innate immune activation into actual cell fate decisions. Through integrated transcriptomic screening across degenerative, STING-inhibited and D-allose-treated conditions, the researchers converged on adrenomedullin 2, or ADM2, a bioactive peptide of the calcitonin gene-related peptide family also known as intermedin. ADM2 had previously been recognised for anti-apoptotic, anti-inflammatory and stress-adaptive functions in other tissues, but its role in the disc was unknown. The team found that ADM2 expression is progressively lost in severely degenerated human disc specimens, restored when cGAS–STING signalling is dampened, and functionally required for nucleus pulposus cells to resist senescence and apoptosis.

The evidence chain is unusually complete. In human tissue, the researchers collected 30 intervertebral disc samples from patients with a mean age of about 48 years, graded by the Pfirrmann system, and showed by immunohistochemistry that ADM2 fades as degeneration advances. In cell culture, oxidative stress induced by hydrogen peroxide and inflammatory stress induced by tumour necrosis factor both suppressed ADM2 at the mRNA and protein levels, while simultaneously driving up senescence markers such as p16, p21 and γH2AX, elevating the senescence-associated secretory phenotype marker IL-6, and flipping the Bax/Bcl-2 balance toward apoptosis with cleaved caspase-3 activation. D-allose treatment reversed essentially all of these changes.

The mechanistic core of the paper lies in the mitochondria. Under intense oxidative or inflammatory stress, the mitophagy apparatus visibly broke down: levels of the mitophagy proteins PINK1 and Parkin fell, the LC3-II/LC3-I ratio dropped, and the autophagic substrate p62 accumulated. Immunofluorescence revealed cytosolic double-stranded DNA piling up in stressed cells, and quantitative PCR of the mitochondrial gene MT-ND1 in cytosolic fractions confirmed that mitochondrial DNA had escaped into the cytoplasm. D-allose restored the mitophagy protein dynamics, curtailed the cytosolic mtDNA burden, and thereby starved the cGAS–STING pathway of its danger signal, as shown by reduced cGAS expression and diminished phosphorylation of STING, TBK1 and IRF3.

Pharmacological and genetic experiments then nailed down causality. When the researchers activated STING with the agonist diABZI, the protective effects of D-allose on senescence and apoptosis markers were abolished. Conversely, inhibiting STING with H-151 phenocopied the sugar’s benefits. The decisive experiment came from mice engineered to lack STING specifically in nucleus pulposus tissue, generated by crossing Sting1-floxed animals with Col2a1-Cre mice. In an annulus fibrosus puncture model of disc degeneration, these knockout mice were markedly resistant to disc height loss, MRI signal deterioration and histological disorganisation. Crucially, giving D-allose to STING-deficient mice provided no additional protection, indicating that the sugar works predominantly through this pathway rather than through some unrelated rescue route.

The in vivo results are the headline act. Systemic D-allose administration at 100 milligrams per kilogram per day, given intraperitoneally for two weeks before and two weeks after disc puncture, significantly ameliorated degenerative changes in C57BL/6 mice. T2-weighted MRI showed improved disc hydration and lower Pfirrmann grades, micro-CT revealed preserved disc height, and histological staining with haematoxylin–eosin and safranin O demonstrated partial restoration of nucleus pulposus architecture. At the matrix level, D-allose reversed the degenerative shift in which the anabolic components COL2A1 and aggrecan decline while the fibrotic COL1A1 accumulates, restoring a healthier extracellular matrix profile. RNA sequencing and Gene Ontology enrichment analysis independently confirmed that extracellular matrix terms and senescence pathways were the transcriptomic signatures most responsive to the treatment.

Functional studies of ADM2 itself rounded out the picture. In mouse discs, ADM2 expression declined progressively with ageing, hinting that its insufficiency may contribute to age-related degeneration. In cultured cells, silencing ADM2 with small interfering RNA was sufficient on its own to induce senescence markers, pro-apoptotic proteins and measurable increases in SA-β-gal positivity and Annexin V–positive apoptotic populations. Enforced ADM2 overexpression did the opposite, shielding stressed cells from senescence and death. Most tellingly, knocking down ADM2 substantially abolished D-allose’s ability to suppress senescence markers and rebalance apoptotic signalling, establishing the peptide as a required mediator of the sugar’s cytoprotection rather than a mere bystander.

Why does the choice of molecule matter so much? Current clinical strategies for disc degeneration largely manage symptoms rather than disease mechanisms, and existing drug candidates for long-term use often carry toxicity or metabolic burdens that limit chronic administration. D-allose, by contrast, is an ultra-low-calorie rare sugar with documented negligible toxicity in animal studies and reported anti-oxidative, anti-inflammatory and anti-apoptotic effects across diverse disease models. Its dual identity as both a bioactive stress-modulating molecule and a potential sugar substitute makes it especially attractive for ageing populations, where cumulative drug toxicity is a serious clinical concern. Rather than acting as a conventional pathway inhibitor, the authors argue, D-allose re-establishes cellular homeostasis by coordinately restoring mitochondrial quality control, limiting mtDNA-driven innate immune activation and preserving ADM2-dependent cytoprotection.

The authors are candid about the limits of the work. The molecular mechanisms governing ADM2 regulation remain to be defined, mitophagy-independent routes of mtDNA reduction may also contribute, and the pharmacokinetics of D-allose in disc tissue were not examined. Given the avascular nature of the intervertebral disc, future studies must determine how the sugar actually reaches the tissue, along with optimal dosing, treatment windows and long-term safety in humans. Still, the conceptual payoff is substantial: a unified framework in which mitophagy failure, cytosolic mitochondrial DNA, cGAS–STING activation and ADM2 silencing converge to decide the fate of disc cells, and a demonstration that this entire axis is therapeutically reversible with a safe, naturally derived molecule. If the findings translate, the humble rare sugar sitting at the edge of the sweetener aisle could become an unexpected ally in the fight against the back pain that afflicts hundreds of millions worldwide.

Subject of Research: D-allose reprogramming of the mitophagy–mtDNA–cGAS–STING–ADM2 axis in intervertebral disc degeneration

Article Title: D-allose reprogrammes the mitophagy–mtDNA–cGAS–STING–ADM2 axis to restore nucleus pulposus cell homeostasis in intervertebral disc degeneration

Article References: Zhao, Z., Li, J., Lei, L., Chen, Y., Li, Z., Zhang, Y., Zheng, Z., Wang, H., Chen, F., & Wang, J. (2026). D-allose reprogrammes the mitophagy–mtDNA–cGAS–STING–ADM2 axis to restore nucleus pulposus cell homeostasis in intervertebral disc degeneration. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01844-7

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01844-7

Keywords: D-allose, intervertebral disc degeneration, mitophagy, mitochondrial DNA, cGAS-STING, ADM2, nucleus pulposus cells, senescence, apoptosis, innate immunity, rare sugar, low back pain

Researchers at Heinrich-Heine-University Düsseldorf, led by Dennis Sohn and colleagues, report that pediatric medulloblastoma cells carrying functional, wild-type p53 do not simply die when bombarded with gamma irradiation. Instead, many of them enter senescence, a terminal and stable arrest of the cell cycle. These zombie-like cells stop dividing but refuse to die, lingering in the tissue for weeks. Crucially, the team showed that these irradiated, senescent tumor cells can then be selectively wiped out with senolytic drugs—compounds designed to eliminate senescent cells. The finding opens a potential two-step strategy: radiation first drives susceptible tumor cells into senescence, and senolytics then clear them away.

The study compared two SHH-activated medulloblastoma cell lines with fundamentally different genetic backgrounds. ONS76 cells carry wild-type p53, the master tumor suppressor that decides a cell’s fate after catastrophic DNA damage. UW228-3 cells carry a mutated, dysfunctional p53. When both lines were exposed to a 20 Gy dose of gamma irradiation, their responses diverged dramatically. UW228-3 cells detached from the culture dish and degraded completely within three to seven days. ONS76 cells, by contrast, remained attached for more than fifty days, flattening out and swelling enormously in both cell body and nucleus—classic hallmarks of senescence.

The molecular evidence followed the morphology. Irradiated ONS76 cells showed a dose-dependent stabilization of p53 and a strong increase in p21, the cyclin-dependent kinase inhibitor encoded by the CDKN1A gene that enforces the senescence arrest. They also accumulated senescence-associated beta-galactosidase activity, a lysosomal enzyme widely used as a senescence marker, and built up lipofuscin, the pigment-like cellular debris characteristic of aged or senescent cells. When the researchers knocked down p53 or p21 using siRNAs, the senescence program collapsed: far fewer cells became senescent and substantially more died instead. This established that radiation-induced senescence in these cells is strictly p53/p21-dependent.

The p53-mutated UW228-3 cells told the opposite story. They showed only a faint, transient rise in beta-galactosidase activity and never developed senescent morphology. Instead, measurements of lactate dehydrogenase release—a marker of plasma membrane destruction—and of DEVDase-like caspase activity revealed that they died by apoptosis, the controlled self-destruction pathway. A pan-caspase inhibitor, q-VD-OPh, completely abolished this cell death while leaving senescence untouched in the wild-type line. The team also employed a recently developed fluorescent lipofuscin binder, GLF16, alongside the amine-reactive viability dye Zombie-violet, allowing simultaneous flow cytometric quantification of senescent and dead cells with sharper discrimination than traditional staining.

The researchers then turned to c-Myc, a proto-oncogene that serves as a crucial negative prognostic factor in medulloblastoma and is known to antagonize p21. Using engineered ONS76 and UW228-3 lines that constitutively overexpress c-Myc, they found that the oncogene tipped the balance away from senescence. In irradiated ONS76/c-Myc cells, p21 protein levels dropped—though p21 mRNA levels did not, indicating that c-Myc interferes with p21 protein production or stability rather than its transcription. Fewer cells adopted senescent morphology, and more cells died, a death that q-VD-OPh could block even though it was not accompanied by elevated caspase activity. Notably, this c-Myc effect operated independently of p53 status. The senescent population in c-Myc-overexpressing cells also proved far more resistant to senolytic treatment, underscoring how oncogene dosage can shape therapeutic vulnerability.

The therapeutic payoff came in the final set of experiments. Seven days after irradiation, when the ONS76 cultures had become fully senescent, the researchers treated them with four senolytic compounds: the BCL-2 family inhibitors Navitoclax and Venetoclax, and the PI3K inhibitors PX-866 and BAY 80-6946 (Copanlisib), the latter already FDA-approved. All four killed the senescent cells in a dose-dependent manner. Navitoclax, however, also eliminated proliferating cells at the highest concentration tested, 30 µM—a reminder of the well-known toxicity problem that has complicated its clinical use, since healthy non-senescent cells are targeted at higher doses. The PI3K inhibitors, by contrast, showed a cleaner specificity for the senescent population.

The clinical logic behind this approach is compelling. Medulloblastoma is unusual among cancers in that relatively few tumors harbor p53 mutations, and in the SHH-activated subtype, p53 status actually defines two distinct risk groups: p53-mutated tumors carry a five-year overall survival of roughly 41 percent and are classified as high risk, while p53 wild-type tumors fare far better at about 81 percent. The new findings suggest that these two groups respond to radiotherapy in mechanistically different ways—senescence in the wild-type setting, apoptosis in the mutated one—a distinction invisible to standard proliferation-based cytotoxicity assays. Senolytic combination therapy would therefore primarily apply to the intermediate-risk, p53 wild-type group, where it could potentially improve outcomes further while reducing the radiation dose needed for tumor control.

The broader context strengthens the case. Senescent cells are not inert; they secrete a cocktail of cytokines and chemokines known as the senescence-associated secretory phenotype, or SASP, which drives chronic tissue microinflammation and can support tumor relapse. Craniospinal irradiation is associated with accelerated brain aging in survivors, and studies in glioblastoma have already shown that eliminating therapy-induced senescent cells with Navitoclax attenuates recurrence. Mouse studies of whole-brain irradiation likewise suggest that senolytic clearance protects cognitive function and the blood-brain barrier. Because senescence can be triggered at lower radiation doses than outright cell death, pairing senolytics with craniospinal irradiation might one day allow clinicians to cure tumors with less radiation exposure while simultaneously mopping up the senescent cells that radiation leaves behind.

Important caveats remain. The entire study was conducted in cell lines rather than animal models or patients, and the exact nature of the c-Myc-driven, caspase-inhibitable cell death observed in the overexpressing cells is still unclear. The authors themselves note that it would be intriguing to test whether JQ1, a bromodomain inhibitor that suppresses c-Myc signaling, could push c-Myc-high, p53 wild-type medulloblastoma cells back into a senescence-permissive state and thereby restore their susceptibility to senolytics. Still, the work is the first to document radiation-induced senescence in medulloblastoma cells and to demonstrate that these cells can be eliminated with existing senolytic drugs. If the strategy survives translation into preclinical models, it could reshape how one of pediatric oncology’s most grueling treatments is delivered—turning the very cells that radiation strands between life and death into targets for a second, cleaner strike.

Subject of Research: Radiation-induced cellular senescence in pediatric medulloblastoma and its targeting by senolytic drugs

Article Title: p53 wild-type/low c-Myc-expressing ONS76 pediatric medulloblastoma cells become senescent after gamma-irradiation and can be eliminated by senolytic substances

Article References: Sonntag, J., Preugschas, R.-L., Jazmati, D., Qin, N., Neuwahl, J., Matuschek, C., Remke, M., Budach, W., Hörner-Rieber, J., & Sohn, D. (2026). p53 wild-type/low c-Myc-expressing ONS76 pediatric medulloblastoma cells become senescent after gamma-irradiation and can be eliminated by senolytic substances. Cell Death Discovery, 12(1), Article 410. https://doi.org/10.1038/s41420-026-03404-4

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03404-4

Keywords: medulloblastoma, senescence, senolytics, p53, c-Myc, p21, gamma irradiation, craniospinal irradiation, Navitoclax, PI3K inhibitors, SASP, pediatric brain tumor

The vulnerability of the kidney tubule to mitochondrial collapse is no accident of biology; it is a direct consequence of what these cells do for a living. Renal tubular epithelial cells, and particularly the proximal tubular epithelial cells that reabsorb the bulk of the filtrate, are packed with mitochondria and depend overwhelmingly on oxidative metabolism to power the solute transporters that keep the body’s salt, water and pH balance in check. That metabolic specialization makes them exquisitely sensitive to a hostile environment. Hypoxia, lipotoxicity, uremic toxins, aging, chronic inflammation and hemodynamic stress all converge on the same target: the oxidative phosphorylation machinery that these cells cannot live without. When the energy supply falters, the entire tubule begins a descent from adaptive stress response into maladaptive repair, and the review is careful to distinguish the two, noting that the same pathways that protect during acute injury can become destructive when the stress never resolves.

At the biochemical level, the review lays out a cascade of interlocking failures. Persistent mitochondrial injury suppresses fatty acid oxidation, the primary fuel-burning pathway of the proximal tubule, and with it oxidative phosphorylation. Levels of nicotinamide adenine dinucleotide, the electron carrier that shuttles energy into the respiratory chain, become depleted. Mitochondrial reactive oxygen species accumulate, overwhelming the local antioxidant systems that include superoxide dismutase 2, thioredoxin 2 and the peroxiredoxins. Mitochondrial DNA becomes destabilized, in part through disruption of mitochondrial transcription factor A, which normally packages and protects the genome inside the organelle. Biogenesis programs governed by PGC-1α falter, the dynamic balance of fission and fusion controlled by DRP1, the mitofusins and OPA1 tips toward fragmentation, and mitophagy, the selective autophagic disposal of damaged mitochondria, loses its precision. None of these failures occurs in isolation; each feeds the others in a self-reinforcing loop.

One of the most consequential threads in the review concerns what happens when that loop breaches the boundaries of the cell. Damaged mitochondria release their contents, and mitochondrial DNA that escapes into the cytoplasm or the extracellular space acts as a damage-associated molecular pattern, tripping the cGAS-STING pathway and the NLRP3 inflammasome and engaging the mitochondrial antiviral-signaling protein MAVS. The result is a sterile inflammatory response that recruits and activates immune cells without any infection being present. Work cited in the review has shown that mitochondrial damage and STING activation lead directly to renal inflammation and fibrosis, and that NAD+ precursor supplementation can prevent the mtRNA- and RIG-I-dependent inflammation that follows kidney injury. In parallel, severely stressed tubular cells undergo inflammatory forms of cell death, including pyroptosis driven by RIPK3-MLKL signaling and mitochondrial calcium/calmodulin-dependent protein kinase II activation, flooding the interstitium with further danger signals.

The review also emphasizes senescence as a critical transition point between organelle failure and tissue-level disease. Tubular cells that survive mitochondrial stress but cannot restore homeostasis may enter a senescent state, acquiring a senescence-associated secretory phenotype that dumps pro-inflammatory cytokines, chemokines and matrix-remodeling enzymes into the surrounding interstitium. Studies cited include evidence that CXC chemokine receptor 2 accelerates tubular senescence through beta-catenin-induced mitochondrial dysfunction, and that pentraxin 3 drives senescence and fibrosis via beta-catenin signaling. Senescent cells also arrest in the G2/M phase of the cell cycle, a state associated with profuse profibrotic secretion. The tubule, in other words, becomes a chronic source of inflammatory and fibrogenic instruction, converting its own internal energy crisis into a multicellular remodeling program.

That program is executed through paracrine communication with the kidney’s other residents. The review organizes this within what it calls a tubule-to-niche framework, tracing how injured tubular epithelial cells signal to fibroblasts, macrophages, endothelial cells and pericytes. Damaged tubules release exosomes and extracellular vesicles, including TNFAIP8-encapsulated vesicles that steer interstitial fibroblast fate and vesicles that induce macrophage glycolysis by stabilizing HIF-1α in diabetic kidney disease. Tubular cell-specific platelet-derived growth factor subunit B has been shown to drive the formation of fibrogenic niches, while myofibroblast activation, the final common pathway of scarring, is reinforced by YAP/TAZ signaling downstream of mechanical and inflammatory cues. Even the vasculature is drawn in: peritubular endothelial cells shift toward glycolysis and microvascular rarefaction, worsening the hypoxia that started the cascade, and macrophage AMPK activated by oxidative stress drives profibrotic crosstalk with tubular cells after ischemic injury.

What distinguishes this review from many earlier syntheses is its methodological self-awareness. The authors explicitly separate causal perturbation from mere temporal or transcriptomic association, model-specific findings from cross-model convergence, and experimental efficacy from genuine clinical translation. They weigh evidence from human biopsy specimens and urinary biomarkers, including urinary mitochondrial DNA as a marker of tissue injury in non-diabetic chronic kidney disease, alongside single-cell RNA sequencing, spatial transcriptomics and kidney organoid models. Large single-cell atlases of healthy and injured human kidney have mapped the fibrotic microenvironment in unprecedented detail, and multi-omic profiling has implicated that microenvironment in disease progression. The review’s central interpretive claim is deliberately measured: mitochondrial dysfunction is not a universal initiating event for all fibrotic kidney disease, but a context-dependent contributor whose importance varies with the type of injury, the timing of observation and the cellular neighborhood in which it occurs.

On the therapeutic front, the review surveys a pipeline of strategies targeting bioenergetics, redox balance, mitochondrial quality control and tubular drug delivery. Restoring fatty acid oxidation has shown benefit in preclinical models, with tubule-specific overexpression of carnitine palmitoyltransferase 1A protecting against fibrosis by restoring mitochondrial homeostasis, and the natural compound hyperoside stabilizing ACAT1 to promote fatty acid oxidation through an L-carnitine-SIRT3 axis. NAD+ boosting has emerged as a particularly active area, with evidence that NAD+ prevents chronic kidney disease by activating renal tubular metabolism and that CD38-mediated NAD+ decline orchestrates fibrosis in obstructive nephropathy. PGC-1α activation by compounds such as ZLN005 and emodin, mitophagy induction through the Nrf2/PINK1 pathway, inhibition of pathological DRP1-mediated fission, and mitochondria-targeted antioxidants such as Mito-TEMPO have all shown antifibrotic effects in experimental systems. Early-phase clinical exploration includes a pilot randomized trial of a mitochondria-targeted ubiquinol on vascular function in chronic kidney disease and a phase 2a trial of the mitochondrial protectant elamipretide during renal artery stenting.

Yet the review is refreshingly blunt about why none of these approaches has yet changed clinical practice. Translation is constrained by disease heterogeneity, since chronic kidney disease arises from diabetes, hypertension, obstruction, toxins and genetic lesions that converge on fibrosis through partly distinct routes. Intervention timing matters enormously, as pathways that protect during acute injury may behave differently once fibrosis is established, and late intervention in animal models has sometimes attenuated proteinuria without slowing the decline of filtration rate. Target specificity, pharmacokinetics and the scarcity of validated human antifibrotic endpoints further complicate the path forward. The authors also note that much of the supporting evidence comes from rodent models such as unilateral ureteral obstruction, whose fidelity to human disease varies. Their synthesis ultimately delivers a dual message: the mitochondrion has earned its place at the center of fibrosis research, but conquering kidney scarring will require matching mitochondrial interventions to the right patients, at the right stage of disease, with endpoints that regulators and clinicians can trust.

Subject of Research: Mitochondrial dysfunction in renal tubular epithelial cells as a driver of fibrosis in chronic kidney disease

Article Title: Mitochondrial dysfunction of renal tubular epithelial cells in chronic kidney disease-associated fibrosis: from organelle homeostasis to multicellular remodeling

Article References: Ni, S., Li, Z., Pan, X., Zhang, Y., & Nie, X. (2026). Mitochondrial dysfunction of renal tubular epithelial cells in chronic kidney disease-associated fibrosis: from organelle homeostasis to multicellular remodeling. Molecular Biology Reports, 53(1), Article 1675. https://doi.org/10.1007/s11033-026-12861-0

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12861-0

Keywords: chronic kidney disease, renal fibrosis, mitochondria, renal tubular epithelial cells, fatty acid oxidation, NAD+, mitophagy, mitochondrial dynamics, mtDNA, inflammation, senescence, single-cell transcriptomics

Clonal haematopoiesis, or CH, arises when somatic mutations in haematopoietic stem cells allow them to outcompete their neighbours and produce expanded populations of mutant blood cells detectable in the peripheral circulation. The condition is remarkably common, present in an estimated 10 to 20 percent of people over the age of 65, and by mid-century the global population over 65 is projected to double, placing hundreds of millions of people at risk of CH-associated complications. Mutations in DNMT3A and TET2 together account for roughly 70 percent of all CH variants, and both have been linked to heightened inflammatory responses in myeloid cells, as well as increased risk of haematologic malignancies and cardiovascular disease. Yet the cell-intrinsic mechanisms connecting these mutations to inflammatory signalling have remained incompletely understood, and clinicians have long struggled to explain why individuals carrying the same mutation can show such different clinical outcomes.

The research team hypothesised that retrotransposable elements, or RTEs, might provide the missing mechanistic link. These genomic parasites, including long interspersed nuclear elements (LINEs), short interspersed nuclear elements (SINEs), and long terminal repeat (LTR) elements also known as human endogenous retroviruses, are normally silenced by DNA methylation and repressive histone modifications. When that silencing breaks down, RTEs can produce RNA and even DNA copies that the cell mistakes for viral invaders, activating innate immune sensors such as cGAS and triggering type-I interferon responses. RTE derepression is increasingly recognised as a hallmark of ageing and has been implicated as a causative factor in cellular senescence, making it a natural suspect in a condition defined by age, mutation, and inflammation.

To test the hypothesis, the researchers analysed peripheral blood mononuclear cell samples from 56 individuals with clonal haematopoiesis and 12 non-CH controls, drawn from a larger population study of 738 otherwise healthy adults over 50 recruited through elective hip replacement surgery at King’s College Hospital in London and The Robert Jones and Agnes Hunt Orthopaedic Hospital in Oswestry. Genomic DNA was sequenced with a customised myeloid panel achieving deep coverage through error-corrected duplex consensus reads, while RNA sequencing without poly(A) selection captured both gene and repetitive element expression, averaging 65.1 million paired-end reads per sample. Participants were stratified into five groups: DNMT3A-mutant high variant allele frequency (VAF above 10 percent, n = 10), DNMT3A-mutant low VAF (n = 30), DNMT3A/TET2 double-mutant (n = 9), TET2-mutant (n = 7), and non-CH controls (n = 12).

The results were unambiguous for the largest expanded clones. High-VAF DNMT3A-mutant clones exhibited widespread derepression of retrotransposable elements, dominated by the LINE:L1 and LTR:ERV1/ERVL families, which are typically repressed by DNA methylation. This pattern fits neatly with prior work showing that DNMT3A loss disrupts de novo methylation and permits repetitive element reactivation in haematopoietic and embryonic stem cells. Interestingly, the high-VAF DNMT3A group was not uniform: the team identified two distinct subgroups, one with markedly elevated RTE expression and another resembling controls, revealing substantial heterogeneity within the same mutation class. The position of the mutation within the protein appeared to matter, with variants affecting the PWWP domain exclusively associated with the RTE-high phenotype, and within the methyltransferase domain most high-VAF mutations showing elevated RTE expression except the recurrent R882H hotspot, which clustered in the RTE-low group. The authors caution that with only ten high-VAF cases these observations require validation in larger cohorts, but they suggest that different DNMT3A mutations may not be biologically equivalent.

Functionally, the RTE-high DNMT3A clones looked dramatically different from their RTE-low counterparts. Gene set enrichment analysis showed that high-VAF DNMT3A clones with elevated RTE expression were enriched for inflammatory signalling pathways, including TNF-alpha/NF-kappaB signalling and broad inflammatory response programmes. At the effector level, these clones expressed significantly higher levels of TNF and the alarmin S100A9, and showed upregulation of multiple interferon regulatory genes, including ISG15, IFI44, IFIT1, IFIT2, and IFIT3, a signature consistent with RTE-derived nucleic acids activating cytosolic sensors and driving type-I interferon responses. The researchers also observed enrichment of pathways involving the Human Silencing Hub (HUSH) and Sirtuin 1 (SIRT1), which they interpret as possible compensatory attempts by alternative epigenetic regulators, including HUSH, Polycomb Repressive Complex 2, and SIRT1, to preserve transcriptional repression in the face of failing DNMT3A-mediated methylation, a coordinated but ultimately failing cellular response rather than random transcriptional noise.

TET2-mutant clones told a completely different story. Far from derepressing retroelements, TET2-mutant haematopoiesis showed a trend towards reduced RTE expression relative to controls, and no significant associations between RTE activity and any of four curated inflammatory and ageing signatures: interferon regulatory genes, TNF-NF-kappaB, senescence, and the senescence-associated secretory phenotype (SASP). Instead, pathway analysis revealed that TET2-mutant clones were enriched for oxidative phosphorylation, reactive oxygen species signalling, and mechanistic target of rapamycin complex 1 (mTORC1) signalling, pointing to a metabolically driven, redox-associated inflammatory phenotype rather than a retroelement-driven one. This aligns with recent publications implicating metabolic and inflammasome pathways, rather than transposable element activation, in TET2-mutant inflammation. In regression analyses, RTE family expression was significantly and positively associated with all four signature scores in DNMT3A high-VAF cases, showed more selective associations with interferon and senescence programmes in low-VAF DNMT3A cases, and showed no significant associations in TET2-mutant cases.

The findings held up under independent scrutiny. Single-cell TARGET-seq data from a separate study, covering five DNMT3A-mutant and three TET2-mutant samples, showed that DNMT3A-mutant cases contained more upregulated RTE subfamilies across individual haematopoietic lineages, with the erythroid and megakaryocyte compartments showing the strongest enrichment and ERV1, ERVL, ERVL-MaLR, and L1 families contributing most. An external validation cohort of 92 healthy middle-aged and older adults from a publicly available RNA-seq dataset, in which RNAVAR mutation calling identified seven DNMT3A and six TET2 high-VAF cases, reproduced the core pattern: retroelement expression correlated significantly with interferon, TNF-NF-kappaB, and senescence signatures in DNMT3A high-VAF clones but not in TET2-mutant cases. Double-mutant clones carrying both mutations occupied an intermediate position, with RTE levels higher than TET2-mutants but lower than DNMT3A high-VAF clones, and attenuated TNF-NF-kappaB and interferon programmes, hinting at non-redundant and possibly antagonistic roles for the two epigenetic regulators.

The study has limitations the authors acknowledge candidly. Bulk RNA sequencing of peripheral blood mononuclear cells can be influenced by differences in cellular composition, and although the TARGET-seq analyses supported cell-intrinsic differences in RTE regulation, the small single-cell cohort cannot fully exclude compositional effects. The number of high-VAF cases remains modest, and, critically, the data demonstrate an association between RTE derepression and inflammatory pathway activation rather than a proven causal relationship, since both could arise as parallel consequences of DNMT3A-associated epigenetic dysregulation. Recurrent co-occurring CHIP mutations were found in only 10 percent of DNMT3A-mutant cases and showed no enrichment in the RTE-high or high-VAF groups, making co-mutations an unlikely explanation for the observed heterogeneity.

Even so, the implications are considerable. By showing that inflammation in clonal haematopoiesis is mutation-specific, with retrotransposon reactivation powering the inflammatory programme of DNMT3A-mutant clones while metabolic and redox dysregulation drive TET2-mutant inflammation, the study lays the groundwork for mutation-specific biomarkers and therapies. If future functional and preclinical studies confirm that modulating RTE activity can dampen the inflammatory phenotype of DNMT3A-mutant clonal haematopoiesis, interventions could one day be tailored to the specific molecular mechanism behind each patient’s mutated clone, replacing a one-size-fits-all approach with precision medicine for age-related blood disorders and, potentially, the cardiovascular and neurodegenerative diseases that travel with them.

Subject of Research: Mutation-specific retrotransposable element derepression and inflammatory signalling in DNMT3A- and TET2-mutant clonal haematopoiesis

Article Title: Retrotransposable element derepression distinguishes DNMT3A-mutant from TET2-mutant clonal haematopoiesis

Article References: Hasan, M., Durandeau, S., Thompson, I. R., Roussotte, H., Tsai, Y.-T., Seymen, N., Gerlevik, S., Bianchini, N., Alishah, K., Albuquerque, M. M., Lewis, J., Bonganay, L., Jakobsen, N. A., Zeisig, B., Irshad, S., Vyas, P., So, E. C. W., Iacoangeli, A., Zheng, X., … Karimi, M. M. (2026). Retrotransposable element derepression distinguishes DNMT3A-mutant from TET2-mutant clonal haematopoiesis. GeroScience. https://doi.org/10.1007/s11357-026-02510-6

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02510-6

Keywords: clonal haematopoiesis, DNMT3A, TET2, retrotransposable elements, LINE-1, endogenous retroviruses, inflammation, ageing, DNA methylation, interferon signalling, senescence, haematopoietic stem cells

The team, led by Yuman Wang and Teding Chang, assembled publicly available and newly generated datasets spanning the lung, heart, brain, vasculature, peripheral blood, intestine, kidney, and liver. After quality control and integration using reciprocal principal component analysis, the atlas comprised 66 samples and 256,949 cells. The compositional analysis revealed a striking pattern: neutrophil abundance rose markedly in several aged tissues. In the liver, the proportion of neutrophils among captured cells climbed from 0.75 percent in young mice to 5.26 percent in old ones; in the lung it rose from 0.88 to 4.14 percent; in vascular tissue from 1.05 to 3.68 percent; and in the intestine from 1.22 to 3.57 percent. The brain, shielded by the blood–brain barrier, showed no comparable increase.

These numbers were not artifacts of sequencing. Immunofluorescence staining for CD11b and myeloperoxidase confirmed dense neutrophil infiltration in aged lung, intestine, vasculature, and liver, while flow cytometry of bone marrow revealed a higher proportion of neutrophils in aged animals. A Bayesian compositional method called scCODA, which treats each biological sample as the unit of inference, independently supported a credible age-associated increase in neutrophil abundance in the liver, with a log2 fold change of 2.61 and an inclusion probability of 0.968.

Functionally, the aged neutrophils looked different at the molecular level. Pseudobulk differential expression analysis, which aggregates cells by sample to avoid inflating statistical significance, identified 26 genes upregulated in neutrophils from aged mice and 985 enriched in young ones. Gene set enrichment showed that glycolysis and reactive oxygen species pathways were activated in the aged cells, while TNF-α and interferon-λ signaling dominated in young ones. When the researchers isolated bone marrow neutrophils and cultured them for four hours, cells from aged mice died more readily and formed more neutrophil extracellular traps—web-like structures of DNA and antimicrobial proteins that, when deployed excessively, can damage surrounding tissue.

The most provocative experiments involved conditioned medium. When culture fluid from aged neutrophils was applied to mouse vascular smooth muscle cells and hepatocytes, both cell types showed increased beta-galactosidase activity, a classic marker of cellular senescence, along with elevated expression of matrix metalloproteinases and senescence-associated proteins such as P16 and P21. Quantitative PCR further revealed increased expression of senescance-associated secretory phenotype genes, including Il6, Tnf, and Ifn, in the exposed cells. In other words, factors released by aged neutrophils appeared to nudge tissue cells toward a stress-associated, inflammatory state.

To dissect neutrophil heterogeneity, the team re-clustered 5,210 neutrophils into 16 transcriptionally distinct subtypes, ranging from TNF-α-producing inflammatory cells to complement-associated, IL-6-expressing, E2F-driven, and unfolded-protein-response states. Several subtypes were preferentially enriched in aged mice, including Neu05-Complement, Neu06-IL6, and Neu08-E2F, while Neu01-TNFA and Neu04-Myc characterized young animals. Maturation scoring suggested that Neu05 and Neu08 resembled early marrow-emigrant neutrophils, mapping closest to the preNeu developmental stage, hinting that aged tissues may be receiving a wave of immature, hyper-responsive cells.

Cross-tissue co-occurrence analysis added a systems-level dimension. The researchers identified seven cellular modules whose member cell types varied in concert across samples. One module, CM3, was the most neutrophil-enriched and contained endothelial cells and fibroblasts alongside aged-enriched neutrophil states, suggesting that neutrophil accumulation covaries with stromal remodeling. CellChat-based ligand–receptor modeling predicted that aged endothelial cells, fibroblasts, and hepatocytes shift from CXCL12-dominant signaling toward CXCL1, CCL7, CCL6, and CCL4 signals. The young-enriched Neu01-TNFα subset preferentially engaged the CXCL12–CXCR4 axis, whereas the age-expanded Neu05 and Neu06 subsets were associated with CXCL1–CXCR2, providing a plausible chemotactic mechanism for the tissue-specific infiltration patterns.

The Neu06-IL6 state emerged as a central character. Pseudotime analysis placed these cells at the distal end of an inferred trajectory, with aged mice showing extended trajectory length and enrichment of Neu06 cells along the late path. The transcription factor CEBPB, which drives emergency granulopoiesis, and STAT3, the canonical IL-6 downstream effector, both increased along the aged ordering. In vitro, recombinant IL-6 activated STAT3 and raised reactive oxygen species production in HL-60 neutrophil-like cells, and conditioned medium from IL-6-stimulated cells induced senescence and matrix-remodeling markers in vascular smooth muscle and liver cell lines—an effect that persisted even after IL-6 washout, implying that IL-6-primed neutrophils release additional factors that propagate the signal.

The study also looked upstream, to the bone marrow. Single-cell analysis of hematopoietic progenitors revealed an aged-enriched state, HPC11, characterized by myeloid-biased genes such as Gata2, Car2, and Prtn3, in contrast to the lymphoid-primed HPC5 state enriched in young mice. Computational perturbation analysis predicted that FGF2 and angiopoietin-like 4 signaling shape the HPC11 program, consistent with the well-known myeloid skewing of aging hematopoiesis and providing a potential source for the flood of atypical neutrophils observed in peripheral tissues.

The authors are careful about causality. Their in vivo findings remain primarily associative, and the term aging-associated neutrophils refers to states enriched in aged organisms rather than neutrophils undergoing canonical senescence. Computational ligand–receptor and regulatory-network inferences are explicitly hypothesis-generating. Still, the partial conservation of these transcriptional programs in human multi-organ data from the Tabula Sapiens atlas, where older donors showed higher proportions of inflammatory and stress-responsive neutrophil states, lends weight to the framework. If future depletion, adoptive-transfer, or IL-6 blockade experiments confirm that these cells actively drive tissue decline, neutrophils may graduate from immune foot soldiers to prime suspects in the biology of aging—and targets for interventions aimed at slowing it.

Subject of Research: Aging-associated neutrophil remodeling across multiple mouse organs identified by single-cell transcriptomics

Article Title: Single‐Cell Mapping Identifies Aging‐Associated Neutrophil Remodeling Across Multiple Organs

Article References: Single‐Cell Mapping Identifies Aging‐Associated Neutrophil Remodeling Across Multiple Organs. (n.d.). https://doi.org/10.1111/acel.70735

Image Credits: AI Generated

DOI: 10.1111/acel.70735

Keywords: neutrophils, aging, single-cell RNA sequencing, IL-6, senescence, bone marrow, granulopoiesis, inflammation, NETs, chemokines, STAT3, geromedicine

Mesenchymal stem cells, or MSCs, are the workhorses of cell-based repair. Harvested from bone marrow or fat, they secrete factors that calm inflammation, encourage angiogenesis, and limit the destructive remodeling that follows a myocardial infarction. Yet clinical trials in ischemic heart disease have produced frustratingly inconsistent results, and the new study points to a likely culprit: senescence. Donor age and the replicative stress of the large-scale expansion needed to produce clinically useful cell numbers both push MSCs into a senescent state, robbing them of the proliferative capacity, migratory behavior, and paracrine output that make them therapeutic in the first place. The harsh, oxygen-starved environment of an infarcted heart can then induce premature senescence in the transplanted cells themselves, further eroding any benefit.

The researchers began with an epidemiological puzzle. Asprosin, encoded by the FBN1 gene that also produces the structural protein fibrillin-1, is known to rise with obesity, driving hepatic glucose release in younger organisms. But when the team measured circulating asprosin in aged mice, they found that despite significant age-related weight gain, levels failed to rise, and aged animals even developed the impaired glucose tolerance that young obese mice display alongside high asprosin. Public transcriptomic datasets revealed why: Fbn1 expression declines with age across a remarkable range of tissues, including white adipose tissue, heart, lung, skeletal muscle, and skin, with the attrition more pronounced in males. Western blotting confirmed matching reductions in asprosin protein in fat, heart, and muscle across young, middle-aged, and old mice.

The human evidence proved equally compelling. In a cohort of 95 normal-weight men, recruited with an a priori power calculation to control for the confounding effect of adiposity, fasting plasma asprosin showed a significant negative correlation with age, with a Spearman coefficient of -0.374. Aging, in other words, appears to override the adiposity-driven regulation that dominates asprosin levels in youth. Single-cell RNA sequencing data from mice, rats, and humans then revealed something unexpected: MSCs, not mature adipocytes, are the dominant FBN1-expressing cell type across fat, muscle, and bone marrow. Pseudotime trajectory analysis showed FBN1 expression falling steadily as multipotent progenitors commit to differentiated lineages, tying the hormone directly to stemness itself. Both chronically aged and acutely senescent MSCs, the latter produced by hydrogen peroxide treatment, showed coordinated declines in Fbn1 transcription, intracellular asprosin, and secreted asprosin.

To test whether asprosin actively governs senescence rather than merely tracking it, the team built CRISPR-Cas9 lentiviral vectors targeting the furin cleavage site within the Fbn1 gene, selectively ablating the hormone while preserving fibrillin-1’s structural role. Asprosin-deficient young MSCs proliferated poorly and, when challenged with hydrogen peroxide, accumulated in the G1 phase of the cell cycle, stained heavily for senescence-associated beta-galactosidase, lost clonogenic potential, and under high oxidative stress underwent increased apoptosis. The mirror-image experiment was more dramatic: overexpressing human asprosin in aged MSCs restored proliferation, pushed cells back into S phase, reduced senescence markers, and enhanced colony formation. Recombinant asprosin produced in human cells, at concentrations from 10 nanograms per milliliter up to 10 micrograms per milliliter without cytotoxicity, reproduced these effects across mouse bone marrow cells, mouse fat-derived cells, and human adipose-derived stem cells.

The mechanism traces through metabolism. Gene set enrichment analysis of asprosin-treated senescent MSCs showed activation of the PI3K-AKT and HIF-1 signaling pathways and a strong enrichment of glycolysis-related gene sets, with no change in oxidative phosphorylation. Seahorse metabolic flux assays confirmed that asprosin raised the extracellular acidification rate, basal glycolysis, and compensatory glycolytic capacity, while lactate production rose and was abolished by the glycolysis inhibitor 2-deoxyglucose. Asprosin upregulated the glucose transporter GLUT1 and rate-limiting enzymes including hexokinase 2 and the phosphofructokinases PFKL and PFKP. Pharmacological inhibition of AKT with MK2206 or of HIF-1alpha with KC7F2 blocked every one of these metabolic shifts, and either inhibitor, or 2-deoxyglucose, erased asprosin’s boosts to proliferation and migration. Notably, mTOR stayed inactive, indicating that asprosin works through a signaling route distinct from classical growth factor pathways. Intriguingly, the proangiogenic paracrine effect, driven by elevated VEGF-A and TIMP-1, depended on AKT-HIF-1 signaling but not on glycolysis itself.

That distinction between bioenergetics and gene regulation is where the study’s most novel layer emerges. Lactate, the end product of glycolysis, is now known to serve as a substrate for histone lactylation, a recently discovered post-translational modification in which lactate is covalently attached to lysine residues on histone proteins. The team showed that asprosin treatment increased global lysine lactylation and, specifically, lactylation of histone H3 at lysine 18, or H3K18la, in senescent MSCs, mirroring the effect of exogenous lactate. Blocking lactate production with sodium oxamate or inhibiting the p300 writer enzyme with A485 abolished both the H3K18la increase and the functional rejuvenation. CUT&Tag sequencing then mapped the epigenetic landscape: asprosin broadened H3K18la deposition genome-wide, and 70 percent of the genes it upregulated carried promoter-associated H3K18la marks. Among the targets were genes governing cell cycle progression and migration, and, critically, a network of DNA repair and replication fidelity genes, including Mcm8, Nucks1, Recql, Grwd1, and Foxp1, whose promoters gained H3K18la enrichment. When asprosin was knocked out, hydrogen peroxide-induced DNA double-strand breaks, marked by gamma-H2AX foci, worsened and repair faltered.

The therapeutic payoff came in a mouse model of acute myocardial infarction. Senescent MSCs transduced with an asprosin-overexpressing lentivirus, or with an empty vector, were injected into the infarct border zone. Immunofluorescent quantification on days 3 and 7 showed significantly higher retention of the asprosin-engineered cells. Over 28 days, mice receiving asprosin-overexpressing MSCs survived at higher rates than untreated infarct controls, while the empty-vector cells conferred no survival benefit. Echocardiography revealed improved left ventricular ejection fraction only in the asprosin group, which also showed reduced heart-to-lung and heart-to-body weight ratios, smaller fibrotic areas on Masson’s trichrome staining, and increased numbers of CD31-positive endothelial and alpha-SMA-positive smooth muscle cells in the peri-infarct zone, indicating robust new vessel formation.

The authors frame their intervention as a third way beyond existing anti-senescence strategies. Senolytics clear damaged cells, and NAD-boosting compounds offer generic metabolic support, but asprosin instead performs what they call functional reprogramming: it directly reverses the senescent state by activating a specific glycolysis-H3K18la axis, restoring a regenerative phenotype without deleting the cells or merely nourishing them. The team also showed that asprosin’s bioactivity depends on post-translational modifications present only in eukaryotic production systems, as bacterially derived protein failed to elicit the same transcriptional response, a caution for any future pharmaceutical development. Significant hurdles remain before clinical translation: the murine infarct model does not capture the comorbidities of human patients, lentiviral overexpression carries a theoretical insertional mutagenesis risk that local, cell-based delivery is designed to minimize, and the MSC-specific asprosin receptor has yet to be identified. Still, with efficacy demonstrated across species, tissue sources, and a broad safe concentration range, asprosin-engineered stem cells now stand as one of the most mechanistically complete rejuvenation strategies yet described, and a promising enhancement partner for the next generation of cardiac cell therapy.

Subject of Research: Asprosin-driven metabolic and epigenetic rejuvenation of senescent mesenchymal stem cells for cardiac repair after myocardial infarction

Article Title: Asprosin-driven metabolic-epigenetic rewiring attenuates mesenchymal stem cell senescence with therapeutic benefits for infarcted hearts

Article References: Zhang, Z., Wang, Z., Zhu, L., Chen, T., Chen, R., Wu, Z., Chen, J., Zhang, H., Wang, M., Liu, J., Hua, N., Hu, S., & Chen, Y. (2026). Asprosin-driven metabolic-epigenetic rewiring attenuates mesenchymal stem cell senescence with therapeutic benefits for infarcted hearts. Journal of Advanced Research, 88, 1055-1075. https://doi.org/10.1016/j.jare.2026.01.073

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.01.073

Keywords: asprosin, mesenchymal stem cells, senescence, histone lactylation, H3K18la, glycolysis, myocardial infarction, FBN1, epigenetics, cardiac repair, regenerative medicine, HIF-1alpha

The study, led by investigators at Shanxi Medical University, tackled a long-standing puzzle in cardiac aging research. Scientists have known that mitochondria, the power plants of the cell, deteriorate as hearts grow old. But the precise mechanism linking that deterioration to the broader decline of the aging myocardium has remained elusive. Because natural aging in mice takes many months and carries high mortality, the team used doxorubicin, a chemotherapy drug well established to produce cardiac damage that closely mimics natural cardiac aging, including mitochondrial dysfunction, enlargement of individual cardiomyocytes, and weakened contraction. They treated young male C57BL/6J mice with repeated low doses of the drug, building up a cumulative regimen that reliably induced senescence in heart tissue.

The first major finding concerned a process called mitophagy, the specialized form of autophagy that clears out damaged mitochondria. Under normal conditions, worn-out mitochondria are tagged, engulfed by autophagosomes, and delivered to lysosomes for degradation, keeping the mitochondrial network healthy. In the aging hearts, electron microscopy revealed a striking accumulation of mitophagosomes—structures that had captured damaged mitochondria but were never processed further. Levels of the autophagy marker LC3B-II and the cargo receptor p62 were simultaneously elevated, a classic signature of a blocked degradative pathway. When the researchers applied chloroquine, a drug that halts lysosomal degradation, to young cells, mitochondrial–LC3B colocalization rose sharply; in aged cells, the drug produced no further increase, indicating that the degradative arm of mitophagy was already saturated. In other words, the aging heart was not failing to initiate mitophagy—it was failing to finish it, creating a traffic jam of half-processed cellular garbage.

The consequences of this congestion were visible throughout the senescent cardiomyocytes. Live-cell imaging showed mitochondria that were shorter, rounder, and more fragmented than those in healthy cells, with fewer branch points and reduced network integrity. Flow cytometry using the MitoSOX probe revealed a significant surge in mitochondrial superoxide, a reactive oxygen species generated by dysfunctional mitochondria. Energy production faltered, oxidative stress mounted, and the senescence program advanced: senescence-associated beta-galactosidase activity climbed, and the proteins p16 and apolipoprotein E—well-established markers of cellular aging—rose in both the mouse hearts and in HL-1 cardiomyocytes treated with doxorubicin in culture.

Enter the therapy. The team isolated mitochondria from murine bone marrow mesenchymal stem cells, a source chosen for its regenerative potential and shared mesodermal origin with cardiomyocytes, and delivered them through the tail vein at 0.5 milligrams per kilogram every two days for six injections. Fluorescent tracing with MitoTracker-labeled mitochondria, monitored by whole-body imaging over 24 hours, confirmed that the organelles reached the cardiac region, and time-lapse microscopy captured them entering cardiomyocytes in culture. The results were dramatic. Echocardiography showed significant recovery of left ventricular fractional shortening and ejection fraction, along with reduced end-systolic volume. Wheat germ agglutinin staining revealed smaller, less hypertrophied cardiomyocytes, senescence staining dropped markedly, and electron microscopy showed fewer mitophagosomes, more intact mitochondria, and restored cristae density. Superoxide levels fell, and the senescence markers p16 and APOE declined in both tissue and cultured cells.

To find the molecular switch behind this rejuvenation, the researchers turned to multi-omics. RNA sequencing of aged versus young hearts identified 27 differentially expressed mitochondrial genes, and one stood out: Bnip3, which encodes an atypical BCL-2 family protein embedded in the mitochondrial outer membrane. BNIP3 normally acts as a mitophagy receptor, recruiting the autophagosome marker LC3B through its LC3-interacting region to initiate mitochondrial clearance. In the aging heart, BNIP3 was dramatically overexpressed, and its expression correlated far more strongly with the autophagy marker Map1lc3b than did PINK1, the canonical ubiquitin-dependent mitophagy pathway, whose Parkin protein levels were unchanged. Crucially, the pattern was conserved across species: hearts from 80-week-old naturally aged mice showed elevated BNIP3, and single-cell RNA sequencing of human heart datasets from GSE156703 and the Heart Cell Atlas revealed significantly higher BNIP3 expression in aged human cardiomyocytes.

Functional experiments confirmed that BNIP3 was not merely a bystander but a driver of senescence. When the researchers forced BNIP3 overexpression in HL-1 cardiomyocytes, the cells developed the full senescent phenotype—elevated p16 and APOE, increased beta-galactosidase staining, and rising levels of LC3B-II and p62 that signaled autophagic congestion. Conversely, when BNIP3 was overexpressed in cells that had received mitochondrial transplantation, the therapy’s benefits vanished: senescence staining returned to aged levels, LC3B–mitochondria colocalization climbed back up, and the accumulated autophagy proteins reappeared. This reversal experiment demonstrated that downregulation of BNIP3 is essential for mitochondrial transplantation to work.

The upstream regulator proved to be an unexpected player. Screening transcription factors altered in the aging heart, the team identified HIF-3α, the least-studied member of the hypoxia-inducible factor family, long regarded mainly as a transcriptional repressor. Here it acted as an activator. Bioinformatic prediction with JASPAR revealed a high-affinity HIF-3α binding site in the Bnip3 promoter, dual-luciferase reporter assays confirmed that HIF-3α could drive Bnip3 transcription, and chromatin immunoprecipitation followed by quantitative PCR pinned down the binding at a specific promoter site. Overexpressing HIF-3α raised BNIP3 levels; silencing it with siRNA lowered them. HIF-1α, the family’s famous member, showed no significant changes, indicating a distinct, non-redundant pathway. HIF-3α was also elevated in aged mouse hearts and aged human cardiomyocytes, and clinical data from heart failure samples in prior literature align with the axis’s upregulation.

Perhaps the most provocative discovery concerns what HIF-3α actually senses: energy. When the researchers measured ATP, they found that mitochondrial transplantation markedly boosted energy levels in aged cardiac tissue. To test whether ATP fluctuations drive the axis, they treated cardiomyocytes with CCCP, a chemical that collapses mitochondrial membrane potential and depletes ATP. ATP levels fell, and HIF-3α rose in response. The emerging model is elegant: as the aging heart’s mitochondria falter and ATP production drops, the energy crisis stabilizes HIF-3α, which switches on BNIP3, floods the cell with mitophagy receptors, and jams the mitophagy flux. Transplanting fresh mitochondria restores ATP, HIF-3α and BNIP3 subside, and the disposal system flows freely again.

The findings arrive as mitochondrial transplantation itself moves into early clinical exploration. Phase I trials in pediatric ischemia-reperfusion injury have already demonstrated preserved cardiomyocyte viability, and systematic reviews support the approach’s potential to restore myocardial bioenergetics, with encouraging safety data showing no immune responses after autologous transplantation. Significant questions remain before aging hearts could be treated this way: the precise mechanism by which HIF-3α senses low ATP is still unknown, whether transplanted mitochondria physically fuse with the recipient’s mitochondrial network has not been directly visualized, and no clinical safety evaluations exist for this application. Delivery routes also pose challenges, from the invasiveness of intramyocardial injection to the low cardiac targeting efficiency of intravenous administration. Still, by identifying the HIF-3α–BNIP3 axis as a druggable control point for mitophagy flux, the study offers something the field has lacked—a concrete molecular explanation for why aging hearts clog their own cleanup machinery, and a demonstration that the clog can be cleared.

Subject of Research: Mitochondrial transplantation therapy for cardiac aging via restoration of mitophagy flux through the HIF-3α–BNIP3 pathway

Article Title: Mitochondrial Transplantation Rejuvenates Aging Heart by Restoring Mitophagy Flux via the HIF‐3α‐BNIP3 Axis

Article References: Mitochondrial Transplantation Rejuvenates Aging Heart by Restoring Mitophagy Flux via the HIF‐3α‐BNIP3 Axis. (n.d.). https://doi.org/10.1111/acel.70720

Image Credits: AI Generated

DOI: 10.1111/acel.70720

Keywords: mitochondrial transplantation, cardiac aging, mitophagy, BNIP3, HIF-3α, senescence, mesenchymal stem cells, doxorubicin, ATP, autophagy flux, cardiomyocytes, Aging Cell

The cells in question are senescent vascular smooth muscle cells, and recent single-cell lineage-tracing studies have pushed a striking reframing of atherosclerosis as a tumor-like disease driven by these very cells. Within plaques, vascular smooth muscle cells undergo clonal expansion, dedifferentiation, and metabolic reprogramming, forming pathological structures that resemble solid tumors. The senescent subset behaves like drug-resistant dormant tumor cells: they persist indefinitely, resist apoptosis, and remodel their surroundings through the senescence-associated secretory phenotype, a cocktail of inflammatory signals that drives necrotic core expansion and thins the fibrous cap that keeps plaques from rupturing. Selectively killing these cells, an approach known as senolysis, has already shown promise for extending lifespan in animal studies, but translating that promise into cardiovascular medicine has been hampered by toxicity concerns with existing drug candidates.

The new study began with a deceptively simple observation. When the researchers modeled senescence in human aortic smooth muscle cells by exposing them to palmitate, a lipid that mimics the lipotoxic stress of atherosclerosis, the cells entered a stable senescent state marked by elevated beta-galactosidase activity and upregulation of the cell-cycle inhibitors p16 and p21. Crucially, the cells also ramped up production of heat shock protein 90 alpha, or HSP90α, a chaperone molecule famous in oncology as a scaffold that supports the survival of tumor cells. Given the parallels between tumorigenesis and atherogenesis, the team hypothesized that senescent smooth muscle cells might exploit the same HSP90α machinery to maintain homeostasis and evade death in the hostile plaque microenvironment.

Proteomic analysis after HSP90α knockdown revealed what that machinery was protecting. Silencing HSP90α specifically activated the PERK/eIF2α/ATF4/CHOP arm of the endoplasmic reticulum stress response, suggesting that high HSP90α levels actively restrain this stress pathway in senescent cells. The team then turned to human tissue, integrating four published single-cell RNA sequencing datasets covering 40 samples of human atherosclerotic lesions from carotid endarterectomy and coronary arteries. In senescent smooth muscle cells identified by co-expression of p21 and p16, HSP90α was highly expressed, but the CHOP stress marker was conspicuously absent. Immunofluorescence of human carotid plaques confirmed the same spatial dissociation, and cultured senescent cells showed suppression of the PERK branch specifically, while the ATF6 and IRE1 branches of the unfolded protein response remained untouched.

The mechanism behind that selective suppression proved to be an elegant piece of molecular scaffolding. Prior work had shown that the kinase AKT can bind to the autophosphorylation site of PERK and block its activation. Using protein-protein docking, co-immunoprecipitation, and domain mapping, the researchers demonstrated that HSP90α holds AKT and PERK together in a ternary complex, with the middle region of HSP90α, amino acids 284 through 620, sufficient to bind both partners. In senescent cells this interaction intensifies, stabilizing AKT and keeping PERK dormant. When HSP90α was removed, AKT degraded rapidly through the proteasome, PERK signaling surged, and the senescent cells began to die. Reactivating the pathway with thapsigargin, a specific inducer of endoplasmic reticulum stress, collapsed mitochondrial membrane potential and pushed the cells into apoptosis while reducing their senescence markers.

The downstream killing mechanism runs through calcium. PERK activation is known to tighten physical contacts between the endoplasmic reticulum and mitochondria, and the team documented exactly that: after HSP90α knockdown or thapsigargin treatment, transmission electron microscopy showed expanded mitochondria-associated ER membranes, fluorescent probes confirmed elevated mitochondrial calcium, and the calcium flux funneled through the mitochondrial calcium uniporter, MCU. Blocking mitochondrial calcium uptake with ruthenium red, or silencing MCU directly, rescued the cells from apoptosis. In other words, the senescent cells survive only as long as PERK stays suppressed; once the brake is released, calcium floods the mitochondria, membrane potential collapses, and the cell self-destructs.

Having defined the target, the team went hunting for a drug. They compiled a dataset of 112 natural products with documented anti-atherosclerotic activity from a literature search spanning 1947 to 2024, then docked each compound against the crystal structure of HSP90α using three independent docking programs and a robust rank aggregation method. The top hit was salvianolic acid A, or SAA, a water-soluble polyphenol from Salvia miltiorrhiza, the red sage root used in traditional Chinese medicine. Its docking score rivaled that of 17-DMAG, a well-characterized synthetic HSP90 inhibitor. Two independent binding assays sealed the case: a cellular thermal shift assay showed that SAA stabilizes HSP90α against heat denaturation, and a biotinylated SAA probe pulled down endogenous HSP90α from cell lysates, confirming direct physical binding.

SAA’s effects on senescent cells were strikingly selective. At concentrations of 20 to 100 micromolar, it triggered apoptosis in senescent smooth muscle cells, reduced p16 and p21, and suppressed secretion of the inflammatory SASP factors IL-1α and IL-6, while leaving normal smooth muscle cells unharmed. Mechanistically, SAA disrupted the HSP90α-AKT-PERK ternary complex, shifted AKT ubiquitination from the K63-linked form toward K48-linked chains that mark proteins for proteasomal destruction, and thereby reactivated PERK signaling. Overexpressing HSP90α reversed all of these effects, and knocking down PERK rescued the cells, confirming that the pathway runs through the complex the team had identified. A cross-linking assay even captured the intact 340-kilodalton ternary complex and watched it dissolve after SAA treatment.

The in vivo results were equally compelling. In ApoE-deficient mice fed a high-fat diet for 20 weeks, intraperitoneal SAA from week 9 onward significantly reduced plaque area, shrank necrotic cores, thickened fibrous caps, and cut lipid accumulation in the aorta, while lowering serum IL-6. Using adeno-associated viruses to manipulate HSP90α specifically in vascular smooth muscle cells, the researchers showed that VSMC-specific knockdown increased p21-CHOP colocalization in plaques, whereas overexpression blunted SAA’s effects and caused a rebound of p21-positive cells. Co-immunoprecipitation from mouse aortas confirmed that SAA weakened the HSP90α-AKT-PERK interaction in living tissue, closing the loop between the cell culture mechanism and the animal outcome.

What makes this work resonate beyond the lab bench is SAA’s clinical head start. Unlike geldanamycin-derived HSP90 inhibitors, whose toxicity has blocked every approval attempt in oncology, SAA is already in a phase II trial for diabetic microangiopathy and two phase I trials for angina pectoris and diabetes, suggesting a tolerability profile that could accelerate translation. The authors caution that mouse-to-human translation is complex and that whether SAA can actually reverse plaque progression will require endpoint clinical trials. Still, the study delivers something the senolytics field has lacked: a senolytic strategy grounded in a defined survival mechanism of the target cells, delivered by a natural compound with human safety data, and validated from molecular docking all the way to plaque stabilization. If the findings hold, the humble red sage root may offer a way to evict the zombie cells that make aging arteries fragile.

Subject of Research: Targeting the HSP90α-AKT-PERK complex in senescent vascular smooth muscle cells as a senolytic strategy against atherosclerosis

Article Title: Salvianolic Acid a Disrupts the HSP90α‐AKT‐PERK Ternary Complex to Alleviate Atherosclerosis by Activating Endoplasmic Reticulum Stress of Senescent Vascular Smooth Muscle Cells

Article References: Guan, X., Lu, M., Cui, X., Zhang, D., Zhang, L., Lin, L., Li, Y., Hu, Y., & Li, C. (2026). Salvianolic Acid a Disrupts the HSP90α‐AKT‐PERK Ternary Complex to Alleviate Atherosclerosis by Activating Endoplasmic Reticulum Stress of Senescent Vascular Smooth Muscle Cells. Advanced Science, Article e77891. https://doi.org/10.1002/advs.77891

Image Credits: AI Generated

DOI: 10.1002/advs.77891

Keywords: atherosclerosis, senescence, senolytics, HSP90α, PERK, endoplasmic reticulum stress, vascular smooth muscle cells, salvianolic acid A, SASP, mitochondrial calcium, AKT, plaque stability

The team focused on the mitochondrial calcium uniporter, or MCU, a channel protein embedded in the inner mitochondrial membrane that ferries calcium ions from the cytosol into the mitochondrial matrix. In mammals, the MCU complex includes pore-forming MCU proteins regulated by accessory components called MICU and EMRE, and decades of work have established that mitochondrial calcium homeostasis is essential for energy production, cell survival, and the decision between life and death. Plants possess their own family of MCU proteins: Arabidopsis carries six putative MCU orthologs, each with a conserved transmembrane domain, a pore loop, and a signature DVME sequence. Previous studies had shown that MCU1, MCU2, MCU3, and MCU5 localize to mitochondria, while MCU6 can target both mitochondria and chloroplasts, and that a triple mutant lacking MCU1, MCU2, and MCU3 shows reduced calcium uptake in roots. What remained unknown was what happens to the entire cell when this calcium gatekeeping system is disturbed.

To answer that question, the researchers first confirmed where the six MCU proteins reside and when they are active. Using fluorescent YFP tags in stable transgenic plants, they observed that the MCU proteins colocalize with mitochondrial markers in leaf and root cells. GUS staining revealed tissue-specific expression patterns: all six genes are active in the root stele, MCU3 is highly expressed in the root apex and cortex, MCU6 dominates the basal meristem, and MCU3, MCU4, and MCU6 are expressed in guard cells. This map of expression hinted that different MCU family members might play specialized roles in different tissues, but also that they share a common job as mitochondrial calcium channels.

The critical technical advance came from genetics. Because the six MCU genes are functionally redundant, the team crossed single mutants to build a sextuple knockdown line, mcu1-6, in which all six genes are expressed at reduced levels. They also created plants that massively overexpress MCU2, with one line showing a ninefold increase in transcript abundance. To watch calcium dynamics in real time, they targeted the calcium-sensitive luminescent reporter aequorin to the mitochondrial matrix and to the cytosol, then challenged seedlings with mannitol, which mimics drought-induced osmotic stress, and sodium chloride, which imposes salt stress. The results were unambiguous. Overexpressing MCU2 amplified the mitochondrial calcium surge, producing higher peak amplitudes and larger response curves, while the sextuple mutant blunted the response, reducing peak amplitudes by an average of 21 percent under mannitol and 26 percent under salt. Crucially, cytosolic calcium signals were unchanged in both lines, demonstrating that MCUs specifically tune mitochondrial calcium uptake without substantially buffering the cytosolic calcium wave that sweeps through stressed cells.

With the calcium phenotype established, the researchers turned to transcriptomics to see how the cell responds. They compared gene expression in the MCU2 overexpression line and the sextuple mutant against two reference conditions: untreated wild type and wild type treated with antimycin A, a drug that blocks the mitochondrial electron transport chain and classically induces the mitochondrial retrograde response. The comparison produced a surprise. Both MCU-perturbed genotypes activated a broad transcriptional program affecting mitochondrial proteostasis—genes encoding mitoribosomal proteins, oxidative phosphorylation complex subunits, the mitochondrial protein import machinery, and matrix proteases were all upregulated. Chaperone genes from four different compartments were induced as well: mitochondrial Hsp70 proteins, cytosolic chaperones, endoplasmic reticulum chaperones, and chloroplast chaperones. Western blots confirmed that mtHsp70 protein accumulated in the overexpression and knockdown lines. None of this multi-compartment chaperone induction appeared in antimycin-treated plants, and the alternative oxidase genes that normally mark the antimycin response stayed silent in the MCU mutants. In other words, disturbing mitochondrial calcium homeostasis triggers a stress program that is fundamentally different from the well-known retrograde response to respiratory chain damage.

The team interprets this pattern as the simultaneous activation of multiple compartment-specific unfolded protein responses. When proteins fail to fold properly in the mitochondrial matrix, the cell does not merely repair the mitochondrion; it appears to mobilize quality-control machinery in the cytosol, the ER, and the chloroplast as well. The researchers suggest that the underlying trigger is likely proteotoxic stress caused by disturbed mitochondrial translation. Supporting this idea, immunoblots showed that mitochondrially encoded subunits of respiratory complexes III, IV, and V—COB, COX1, ATP4, and ATP8—were reduced in the MCU-perturbed plants, while some nuclear-encoded subunits accumulated, creating a stoichiometric imbalance between the two genomes that supply the respiratory chain. This kind of mitonuclear protein imbalance is a classic activator of the mitochondrial unfolded protein response in animals, and the plant transcriptional profile resembled the interorganellar proteostasis program described in yeast, suggesting deep evolutionary conservation of this alarm system.

But the story did not end with transcription. Quantitative mass spectrometry of the proteome revealed that roughly half of the differentially abundant proteins in the sextuple mutant did not follow their transcript levels. Most strikingly, of the 194 cytosolic ribosomal protein genes whose abundance changed, about 58 percent showed reduced protein despite elevated mRNA. The same paradox appeared for chloroplast and mitochondrial ribosomal proteins and for pentatricopeptide repeat proteins, tetratricopeptide repeat proteins, and pseudouridine synthases—proteins that perform RNA editing and translation inside organelles. To investigate this apparent post-transcriptional repression, the researchers performed polysome profiling, separating actively translated mRNAs on polysomes from poorly translated ones on monosomes. While antimycin treatment caused a dramatic global shift from polysomes to monosomes, the MCU-perturbed plants showed only a mild global shift. Instead, translational efficiency analysis revealed a highly selective repression: genes involved in mitochondrial RNA metabolism and RNA modification lost translational efficiency in both the overexpression line and the sextuple mutant, with about 81 percent of RNA modification transcripts showing low translational efficiency. More than half of all transcriptionally induced cytosolic ribosomal protein mRNAs were also translationally repressed.

This selective translation program points to specific molecular effectors. In mammalian cells, the kinase GCN2 phosphorylates the translation initiation factor eIF2α to dampen protein synthesis during stress, while the TOR pathway senses energy status. The proteomic and immunoblot data told an unexpected tale: in the MCU-perturbed plants, eIF2α protein abundance and its phosphorylated form were both reduced, along with several translation initiation components, while TOR and the energy-sensing kinases KIN10 and KIN11 were largely unaffected. Antimycin treatment produced the opposite signature—increased KIN10 and KIN11 phosphorylation and reduced TOR, with no change in eIF2α. The authors propose that these two pathways mediate distinct types of mitochondrial stress: the TOR-S6K energy-sensing module handles the short-term, acute crisis caused by electron transport chain poisoning, whereas the eIF2α pathway manages the long-term, mild proteotoxic stress of chronic calcium imbalance. Counterintuitively, reducing eIF2α phosphorylation may be protective, preventing a catastrophic shutdown of protein synthesis during prolonged stress—an adaptive mechanism recently proposed in mammalian cells that now appears to operate in plants as well.

The physiological consequences of this molecular storm were visible to the naked eye. Plants with impaired MCU-controlled calcium homeostasis grew more slowly, with reduced leaf area that correlated with MCU2 expression levels in the overexpression lines. They also senesced prematurely, yellowing their older leaves weeks before wild type plants, and the timing of senescence tracked MCU2 dosage. Under osmotic stress induced by mannitol, both the overexpression lines and the sextuple mutant were significantly more sensitive than wild type, with markedly reduced fresh weight. These phenotypes establish a direct link between mitochondrial calcium homeostasis and the core stress biology traits of growth, aging, and stress resistance, and they suggest that the cross-compartmental proteostatic response is not merely a curiosity of gene expression but a determinant of plant fitness.

The study does have acknowledged limitations. The aequorin reporter lacks the sensitivity to resolve basal calcium levels or subtle changes after antimycin treatment, so modest differences in resting mitochondrial calcium cannot be excluded. The upstream regulators of MCU-mediated calcium signaling remain undefined, and future work with established calcium influx mutants such as osca and moca1 will be needed to position the uniporters within the broader calcium signaling hierarchy. The detailed molecular analysis also focused on a single high-expression MCU2 overexpression line, leaving open the possibility that individual MCU isoforms have distinct intrinsic activities. Even so, the findings provide a compelling new framework: mitochondrial calcium homeostasis, mitochondrial translation, and cellular proteostasis are woven together through an interconnected organelle quality control network that integrates transcriptional activation with selective translational repression. As climate change intensifies drought and salinity stress on crops, understanding and potentially engineering this calcium-triggered proteostatic alarm could offer new genetic targets for breeding more resilient plants.

Subject of Research: Mitochondrial calcium homeostasis and cross-compartmental proteostatic signaling in Arabidopsis

Article Title: Perturbation of mitochondrial Ca2+ homeostasis activates cross-compartmental proteostatic response in Arabidopsis

Article References: Perturbation of mitochondrial Ca2+ homeostasis activates cross-compartmental proteostatic response in Arabidopsis. (n.d.). https://doi.org/10.1007/s44154-026-00314-4

Image Credits: AI Generated

DOI: 10.1007/s44154-026-00314-4

Keywords: mitochondria, calcium signaling, mitochondrial calcium uniporter, Arabidopsis, unfolded protein response, proteostasis, retrograde signaling, eIF2α, translation regulation, plant stress, ribosomal proteins, senescence

The significance of the finding lies in how it connects two previously separate threads of biology. CD47 has long been studied in oncology and immunology because it broadcasts a so-called “don’t eat me” signal. When CD47 on a cell’s surface engages its receptor, signal regulatory protein alpha (SIRPα), on macrophages and other myeloid cells, it triggers inhibitory pathways that suppress phagocytosis and efferocytosis, the orderly clearance of dead and dying cells. Cancer cells exploit this signal to evade immune surveillance, which is why anti-CD47 antibodies are being developed as cancer therapeutics. Separately, CD47 also binds thrombospondin-1 and integrins, pathways that regulate nitric oxide signaling, vascular tone, oxidative stress, and cell survival. Prior work has linked CD47 upregulation to cardiac hypertrophy, fibrosis, ischemia-reperfusion injury, and atherosclerosis, while CD47 inhibition has been shown to protect cardiac function in several models.

What remained unknown was whether CD47 participates in cardiac aging itself, particularly the accelerated aging induced by chemotherapy. Clues had been accumulating. In skeletal muscle stem cells, CD47 levels rise with age, and as senescence markers such as beta-galactosidase activity increase, the density of CD47 on the cell surface climbs in parallel, forming what researchers have described as a molecular signature of aging. Aberrant CD47 expression has also been documented in aged fibroblasts, epithelial cells, and red blood cells. Because doxorubicin inflicts a characteristic cascade of injuries on the myocardium, including DNA intercalation, interference with topoisomerase-II-dependent DNA repair, chromatin disruption through nucleosome destabilization and histone eviction, mitochondrial dysfunction, oxidative stress, impaired autophagy, and inflammatory activation, the Chinese team hypothesized that CD47 might serve as the underexplored link between these upstream insults and persistent, age-like cardiac remodeling.

To test this, the researchers first turned to public transcriptomic databases. They analyzed two independent cardiac aging datasets from the Gene Expression Omnibus: a rat dataset (GSE173360) comparing six-month-old adult males with 24-month-old aged animals, and a mouse dataset (GSE225576) comparing young and aged hearts. In both species, CD47 expression was significantly elevated in aged heart tissue, and functional enrichment analysis of the differentially expressed genes revealed alterations in metabolic and myocardial contraction-related pathways. The consistency across two mammalian species suggested that CD47 upregulation is a conserved feature of cardiac aging rather than a quirk of one model system.

The team then built a doxorubicin-induced cardiac aging model in six-month-old male C57BL/6J mice. Animals received weekly intraperitoneal injections of doxorubicin at 2.5 milligrams per kilogram for six consecutive weeks, a regimen designed to mimic the cumulative cardiac stress seen in chemotherapy patients. Molecular analysis confirmed that the model worked: mRNA levels of canonical aging markers, including p53, p16, p21, and the proliferation marker KI67, were markedly elevated in the hearts of doxorubicin-treated mice. Crucially, both the mRNA and protein levels of CD47 were significantly increased in these aged hearts, as demonstrated by quantitative PCR, western blotting, and immunofluorescent staining of cardiac tissue sections.

With the model established, the researchers introduced their therapeutic intervention: ligufalimab, also known as AK117, a humanized IgG4 monoclonal antibody that targets CD47 and blocks its interaction with SIRPα without altering CD47 expression itself. Mice receiving doxorubicin plus weekly ligufalimab at 1 milligram per kilogram showed a striking molecular shift. Expression of the senescence effectors p21 and p16 declined significantly in the heart, indicating that CD47 blockade was not merely improving hemodynamics but was actually dampening the senescence-associated signaling that underlies age-like cardiac remodeling. Echocardiographic assessment, performed after the final dose under pentobarbital anesthesia, told a parallel story. Left ventricular fractional shortening and ejection fraction, the standard functional measures of cardiac pumping performance, dropped sharply in doxorubicin-treated mice compared with saline controls, but ligufalimab co-treatment significantly improved both parameters.

To probe whether the effect was conserved in human cells, the team turned to AC16 cardiomyocytes, a human cardiac cell line derived from a male donor. Cells treated with 0.1 micromolar doxorubicin for 48 hours developed a clear senescence-like phenotype, with p16 and p21 mRNA rising steeply and CD47 mRNA and protein increasing in parallel. When ligufalimab at 0.1 micrograms per milliliter was added alongside the chemotherapy, p21 fell at both the mRNA and protein levels, p16 declined at the mRNA level, and senescence-associated beta-galactosidase staining revealed a notable reduction in cellular aging. The convergence of results from living mouse hearts and cultured human cardiomyocytes strengthens the argument that the protective effect is not species-specific or model-dependent, and it points toward genuine translational relevance.

Mechanistically, the authors propose a compelling explanation centered on the CD47-SIRPα axis. During doxorubicin-induced cardiac injury, upregulated CD47 on stressed or senescent cardiomyocytes may shield those cells from macrophage-mediated clearance, allowing damaged cells to linger and continue broadcasting inflammatory and profibrotic signals throughout the myocardium. By blocking CD47, ligufalimab may restore the removal of injured and senescent cells, limit chronic inflammatory amplification, and thereby interrupt the self-reinforcing loop that converts acute chemotherapy injury into persistent age-like remodeling. The observed reduction in p53, p16, and p21 after CD47 blockade is consistent with this interpretation, suggesting that the antibody attenuates senescence-associated signaling itself rather than simply propping up contractile performance. The finding also reframes CD47 as more than an immune checkpoint molecule: it appears to function as a stress-responsive regulator that integrates cellular damage, immune clearance, and cardiovascular remodeling.

The authors are careful to note that important questions remain before this science can reach the clinic. The downstream mechanisms are not yet fully defined; future work should directly assess SIRPα-dependent efferocytosis, thrombospondin-1/CD47 signaling, mitochondrial function, reactive oxygen species production, inflammatory cytokines, and senescence-associated secretory factors. It is also unclear whether the benefits of anti-CD47 therapy are immune-mediated, intrinsic to cardiac cells, or both, and cell-specific genetic models, macrophage-depletion experiments, and efferocytosis assays will be needed to disentangle these contributions. Because CD47 is broadly expressed and plays essential roles in immune surveillance and red blood cell clearance, clinical translation will demand careful optimization of treatment timing, dose, tissue specificity, and safety. The researchers suggest that transient or cardiac-targeted CD47 inhibition might retain cardioprotective effects while minimizing systemic adverse effects. They also acknowledge that the study focused on male mice and on the heart alone, leaving open whether CD47 regulates aging in other organs and in female animals. Even so, the study marks a notable step: it identifies CD47 as both a potential biomarker of cardiac aging and a druggable contributor to chemotherapy-induced cardiac decline, raising the prospect that oncologists might one day protect the aging heart while still unleashing doxorubicin’s full anticancer power.

Subject of Research: The role of CD47 in doxorubicin-induced cardiac aging and its blockade as a cardioprotective strategy in male mice

Article Title: CD47 is a regulator in doxorubicin‐induced cardiac aging in male mice

Article References: Yan, A., Mai, R., Cao, T., Duan, C., Liu, S., & Wang, X. (2026). CD47 is a regulator in doxorubicin‐induced cardiac aging in male mice. Physiological Reports, 14(18), Article e71111. https://doi.org/10.14814/phy2.71111

Image Credits: AI Generated

DOI: 10.14814/phy2.71111

Keywords: CD47, doxorubicin, cardiac aging, cardiotoxicity, senescence, ligufalimab, SIRPα, efferocytosis, cardiomyocytes, echocardiography, chemotherapy, heart failure